Apic Bio Announces Presentations at the American Society of Gene and Cell Therapy’s 23rd Annual Meeting

The posters include:

Abstract Title: High Efficiency Downstream Processing and Enrichment of Full AAV Particles Produced from Suspension HEK293 Cells (abstract #467)
Presenter: Scott Loiler, Chief Technology Officer, Apic Bio
Session Title: Vector and Cell Engineering, Production or Manufacturing
Date/Time: Tuesday May 12, 2020 5:30 PM to 6:30 PM ET

Abstract Title: Optimizing Suspension HEK293 Transfection Processes for AAV Productivity (abstract #859)
Presenter: Scott Loiler Chief Technology Officer, Apic Bio
Session Title: Vector and Cell Engineering, Production or Manufacturing
Date/Time: Wednesday May 13, 2020 5:30 PM to 6:30 PM ET

Abstract Title: Bridging Efficacy Data in an ALS Mouse Model with Clinical Route of Administration in Nonhuman Primates to Derive a Meaningful Clinical Dose Range (abstract #1114)
Presenter: Randal Hand, Senior Scientist, Apic Bio
Session Title: Neurological Diseases
Date/Time. Thursday May 14, 2020 5:30 PM to 6:30 PM ET

About Apic Bio

Apic Bio is an innovative gene therapy company focused on developing first-in-class treatment options for rare, undertreated neurological and liver diseases. The Company’s lead program is an adeno-associated (AAV)-based gene therapy for the treatment of the copper zinc superoxide dismutase 1 (SOD1) genetic form ALS. Preclinical studies of additional genetic forms of ALS (C9Orf72) and Alpha-1 Antitrypsin Deficiency (Alpha-1) are ongoing. The Company is also advancing discovery programs for two undisclosed CNS indications that leverage its proprietary silence and replace THRIVE™ platform. The Company is backed by leading and disease-centric investors, including Morningside Ventures, ALS Investment Fund, and The Alpha-1 Project (TAP). For more information please visit www.apic-bio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200428006046/en/